Statement From Kerlan Jobe Orthopaedic (KJOC) President Daniel Kharrazi Regarding the Passing of Pitching Great Tommy John
Statement From Kerlan Jobe Orthopaedic (KJOC) President Daniel Kharrazi Regarding the Passing of Pitching Great Tommy John
This past weekend our nation lost a truly great American and baseball lost a titan whose courage and fortitude, in addition to his natural talent, paved the way for others like him to realize the benefits of sports orthopedic medicine. Our late former distinguished co-founder and colleague, Dr. Frank Jobe, collaborated with Tommy to not only allow him to benefit baseball, but help countless others engaged in non-athletic endeavors. Tommy John surgery is now recognized worldwide and KJOC is proud of Dr. Jobe’s role in pioneering this innovative medical procedure.
KJOC, an independent sports orthopedic medical group, will continue to innovate and develop new procedures in orthopedic sports medicine. We strive to honor the traditions and commitment of our founders Dr. Robert Kerlan and Dr. Frank Jobe to foster the practice of sports medicine without interference by outside corporate interests. Such is our mission.
About Kerlan-Jobe Orthopaedic Clinic
For nearly half a century, Kerlan-Jobe has been the nation’s premier sports medicine provider, renowned for treating professional athletes, first responders, and patients from all walks of life. Known for its groundbreaking surgical techniques, including the pioneering Tommy John surgery, Kerlan-Jobe has set the standard for orthopaedic care in the United States. The clinic has also established prestigious educational fellowships and remains a cornerstone of orthopaedic innovation and community service in Los Angeles. Kerlan-Jobe’s physicians have provided vital treatment to the general public, professional and amateur athletes from around the world, and unparalleled service to the local community.
Brian Sun
213-892-9222
brian.sun@nortonrosefulbright.com
Alexis Braun
212-318-3103
alexis.braun@nortonrosefulbright.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260817701052/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States